Multispecific antibodies for immuno-oncology
作者： Jamie Campbell , Nikole SANDY , Cassandra VAN KRINKS , Stephen John ARKINSTALL , Volker Germaschewski
DOI:
关键词:
摘要: Multispecific antibody having a binding site for ICOS and second antigen, e.g., an immune checkpoint molecule such as PD-L1. Use of the multispecific in immuno-oncology, including treatment solid tumours.
lens.org 参考文章(448)
Mitsuaki Isobe, Seiichi Suzuki, Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM ,(2004)
Randal R. Ketchem, Courtney Beers, Jason C. O'neill, Ian Nevin Foltz, Julia C. Piasecki, Gitr antigen binding proteins ,(2014)
Thomas E. Lane, Daniela J.J. Carr, Methods for treating ocular inflammation by neutralizing cxcl10 activity ,(2003)
Linda Liang, Robert H. Pierce, Michael Bigler, Patricia Bourne, Antibodies that bind to human programmed death ligand 1 (pd-l1) ,(2013)
Thomas E. Lane, Methods for treating rheumatoid arthritis ,(2004)
Justin Wong, Maximiliano Vasquez, Antibodies that bind csf1r ,(2011)
Inger Sandlie, Ingrid Choi, Melvyn Little, ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN Cν3 AND Cν4 DOMAINS ,(2001)
Ling Huang, Leslie S. Johnson, Cd3-binding molecules capable of binding to human and non-human cd3 ,(2012)
Dominik Ruettinger, Katharina Wartha, Sabine Hoves, Carola Ries, Combination therapy of antibodies against human csf-1r and tlr9 agonist ,(2014)
Jesus Pfizer Global R D Gomez-Navarro, Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer ,(2005)